NEJM July 2026 Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
NEJM July 2026 Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.
-
ナレーター：
-
著者：
This study evaluates the effectiveness of teclistamab, a specialized bispecific antibody, as an early treatment option for patients facing a relapse of multiple myeloma. By comparing this novel therapy against standard clinical drug combinations, researchers found that teclistamab significantly extended progression-free survival and resulted in a dramatically higher rate of complete disease response. While the treatment demonstrated superior efficacy in slowing cancer growth and improving overall survival, it also presented a higher risk of serious infections and unique immune-related side effects. Ultimately, the text establishes teclistamab as a potent alternative for patients who have already cycled through several traditional lines of therapy.